Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HUM stock price vs HUBS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HUBS's multiple
Needs HUBS P/E.
Implied fair value · at HUM's multiple
Needs HUM P/E.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HUM FY 2025 (ended Dec 31, 2025) · HUBS FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HUMANA INC · implied price per share
Bear
-$135.60
Base
-$159.53
Bull
-$183.46
HubSpot, Inc. · implied price per share
Bear
$13.65
Base
$16.06
Bull
$18.47
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.73x
0.27x
Net debt / EBITDA
Leverage against operating earnings
-1.78x
-1.60x
Cash and equivalents
Liquid reserves on the balance sheet
$19.90B
$882.24M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$12.95B
$551.06M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe HUM's current earnings power and 25.3% ROIC deserve a materially lower discount than HUBS's software-like multiples, then HUM looks worth accumulating because it is priced far below HUBS-implied valuation while still showing solid balance-sheet and distress metrics.
The P/E-based implied price of $2,745.13 suggests a 633.0% upside versus HUM's current price of $374.50, but that gap is driven by a direct multiple comparison to HUBS's far richer 279.0x P/E. On revenue and EBITDA bases, HUM is also cheaper at 0.3x P/S and 9.7x EV/EBITDA versus HUBS at 3.9x P/S and 57.9x EV/EBITDA, indicating a persistent valuation discount.
Supporting Metrics
